<article id="tolerability_DME" class="slide" data-ag-name="Tolerability DME">
  <div class="tab-title">DME</div>
  <h2 class="slide-title">DEMONSTRATED TOLERABILITY<sup class="footnote-link">1</sup></h2>
   <p>Of the 5940 intravitreal injections during Phase III trials, one serious AR related to the injection procedure (retinal&nbsp;detachment) occurred.</p>
  <div class="chart-header">Most common ARs reported in ≥5% of patients treated with EYLEA<sup class="reg">&reg;</sup><span class="asterisk">*</span></div>
  <div class="chart-img"><img src="content_EN/img/charts_t-dme.png" /></div>
  <div class="keys"><div class="chart-key">* Combined safety data for VISTA<sup>DME</sup> and VIVID<sup>DME</sup> trials with up to 52 weeks’ exposure.</div></div>
</article>